These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11972410)

  • 1. MMR vaccine: review of benefits and risks.
    Miller E
    J Infect; 2002 Jan; 44(1):1-6. PubMed ID: 11972410
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccines for measles, mumps and rubella in children.
    Demicheli V; Jefferson T; Rivetti A; Price D
    Cochrane Database Syst Rev; 2005 Oct; (4):CD004407. PubMed ID: 16235361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MMR and the measles crisis.
    Murphy JF
    Ir Med J; 2000; 93(2):36. PubMed ID: 11037244
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
    Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MMR vaccination, Crohn's disease and autism: a real or imagined "stomach ache/headache?".
    Passwell JH
    Isr Med Assoc J; 1999 Nov; 1(3):176-7. PubMed ID: 10731330
    [No Abstract]   [Full Text] [Related]  

  • 6. [Measles, mumps, rubella: important health risks].
    Rev Infirm; 2000 Oct; (64):13-5. PubMed ID: 11288443
    [No Abstract]   [Full Text] [Related]  

  • 7. The MMR Vaccine and Autism.
    DeStefano F; Shimabukuro TT
    Annu Rev Virol; 2019 Sep; 6(1):585-600. PubMed ID: 30986133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pendulum swings back to MMR.
    Dixon B
    Curr Biol; 2001 Oct; 11(20):R807. PubMed ID: 11676930
    [No Abstract]   [Full Text] [Related]  

  • 9. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MMR vaccination: new thought.
    Deshmukh V
    Indian Pediatr; 2006 Jun; 43(6):555-6. PubMed ID: 16820670
    [No Abstract]   [Full Text] [Related]  

  • 11. Immediate injection pain in infants aged 18 months during vaccination against measles, mumps and rubella with either Priorix or MMR-II.
    Knutsson N; Jansson UB; Alm B
    Vaccine; 2006 Jul; 24(31-32):5800-5. PubMed ID: 16765490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine.
    St Sauver JL; Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Hum Immunol; 2005 Jul; 66(7):788-98. PubMed ID: 16112026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MMR: where are we now?
    Elliman D; Bedford H
    Arch Dis Child; 2007 Dec; 92(12):1055-7. PubMed ID: 17626143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines, Crohn's disease and autism.
    Afzal MA; Minor PD
    Mol Psychiatry; 2002; 7 Suppl 2():S49-50. PubMed ID: 12142950
    [No Abstract]   [Full Text] [Related]  

  • 15. Why do parents hesitate to vaccinate their children against measles, mumps and rubella?
    Alfredsson R; Svensson E; Trollfors B; Borres MP
    Acta Paediatr; 2004 Sep; 93(9):1232-7. PubMed ID: 15384890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between MMR vaccine and autism.
    Klein KC; Diehl EB
    Ann Pharmacother; 2004; 38(7-8):1297-300. PubMed ID: 15173555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMR, measles, and the South Wales Evening Post.
    McCartney M
    BMJ; 2013 Apr; 346():f2598. PubMed ID: 23610382
    [No Abstract]   [Full Text] [Related]  

  • 18. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
    Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
    J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants.
    Yerkovich ST; Rowe J; Richmond P; Suriyaarachchi D; Heaton T; Hollams E; Ladyman C; Serralha M; Sadowska A; Loh R; Wesselingh SL; Sly PD; Holt PG
    Vaccine; 2007 Feb; 25(10):1764-70. PubMed ID: 17224218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons Learned from Publicizing and Retracting an Erroneous Hypothesis on the Mumps, Measles, Rubella (MMR) Vaccination with Unethical Implications.
    Khan H; Gasparyan AY; Gupta L
    J Korean Med Sci; 2021 May; 36(19):e126. PubMed ID: 34002546
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.